Skip to search formSkip to main contentSkip to account menu

gefitinib

Known as: 4-(3Chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine, gefitinib [Chemical/Ingredient] 
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal… 
National Institutes of Health

Related topics

Related topics

17 relations

Broader (3)

Antineoplastic AgentsProtein Kinase InhibitorsQuinazolines
Drug AllergyEGFR protein, humanHER1 Antagonists [MoA]Lung Neoplasms

Narrower (2)

IressaZD 1839

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian…
Highly Cited
2014
Highly Cited
2014
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
2014
2014
Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line
Previous studies have observed that Paris saponin I (PSI) exerts a wide range of pharmacological activities, including cytotoxic… 
Highly Cited
2011
Highly Cited
2011
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
2011
2011
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild‐type nonsmall cell lung cancer treated with EGFR‐tyrosine kinase inhibitors
In patients with nonsmall cell lung cancer (NSCLC), several studies have demonstrated a positive correlation between somatic… 
Review
2010
Review
2010
Long-term survivors of more than 5 years in advanced non-small cell lung cancer.
2007
2007
Identification of EGFR mutations in esophageal cancer.
Highly Cited
2006
Highly Cited
2006
Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo
Purpose: Epidermal growth factor receptor (EGFR) overexpression has been implicated in the development of head and neck squamous… 
Highly Cited
2003
Highly Cited
2003
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines
BackgroundClinical trials of gefitinib (Iressa, ZD1839) in combination with cytotoxic agents have been carried out or are ongoing… 
Highly Cited
1997
Highly Cited
1997
Modulation of glutamate release by a nitric oxide/cyclic GMP-dependent pathway.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)